{
    "clinical_study": {
        "@rank": "72350", 
        "arm_group": {
            "arm_group_label": "Treatment", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "The study aims to understand, using radiolabelled PF-04449913, how this compound is modified\n      by the body once it is absorbed. The study also aims to understand how much of the compound\n      is broken down and how much leaves the body unchanged."
        }, 
        "brief_title": "A Study To Understand How Radiolabelled PF-04449913 Is Taken Up By The Body, Broken Down And Then Removed From The Body", 
        "completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy male subjects between the ages of 18 and 55 years (inclusive):Healthy is\n             defined as no clinically relevant abnormalities identified by a detailed medical\n             history, full physical examination, including blood pressure and pulse rate\n             measurement, 12-lead ECG and clinical laboratory tests.\n\n          -  Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight >50 kg (110\n             lbs).\n\n          -  An informed consent document signed and dated by the subject.\n\n          -  Subjects who are willing and able to comply with scheduled visits, treatment plan,\n             laboratory tests, and other study procedures.\n\n        Exclusion Criteria:\n\n          -  Evidence or history of clinically significant hematological, renal, endocrine,\n             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or\n             allergic disease (including drug allergies, but excluding untreated, asymptomatic,\n             seasonal allergies at time of dosing).\n\n          -  Subjects enrolled in a previous radionucleotide study or who have received\n             radiotherapy within 12 months prior to screening or such that total radioactivity\n             would exceed acceptable dosimetry.\n\n          -  A positive urine drug screen or urine cotinine test\n\n          -  12 lead ECG demonstrating QTc >450 or a QRS interval >120 msec msec at Screening.  If\n             QTc exceeds 450 msec, or QRS exceeds 120 msec, the ECG should be repeated two more\n             times and the average of the three QTc values should be used to determine the\n             subject's eligibility.  Subjects with family history of myocardial infarction,\n             congenital long QT syndrome, torsades de pointes or clinically significant\n             ventricular arrhythmias.  Subjects should be within normal range of potassium,\n             magnesium and calcium at screening."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "6", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 8, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02110342", 
            "org_study_id": "B1371009"
        }, 
        "intervention": {
            "arm_group_label": "Treatment", 
            "description": "Single oral dose of 100 mg PF-04449913 + 100\u00b5Ci of [14C] PF-04449913", 
            "intervention_name": "[14C] PF-04449913", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "PF-04449913", 
            "[14C]PF-04449913", 
            "Human ADME", 
            "Radiolabel", 
            "Mass Balance", 
            "Pharmacokinetics"
        ], 
        "lastchanged_date": "May 28, 2014", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B1371009&StudyName=A%20Study%20To%20Understand%20How%20Radiolabelled%20PF-04449913%20Is%20Taken%20Up%20By%20The%20Body%2C%20Broken%20Down%20And%20Then%20Removed%20From%20The%20Body"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Madison", 
                    "country": "United States", 
                    "state": "Wisconsin", 
                    "zip": "53704"
                }, 
                "name": "Pfizer Investigational Site"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase One Open-Label Single-Radiolabeled Dose Study To Investigate The Absorption, Metabolism, And Excretion Of [14C] PF-04449913 In Healthy Male Volunteers", 
        "overall_contact": {
            "last_name": "Pfizer CT.gov Call Center", 
            "phone": "1-800-718-1021"
        }, 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "AUC (0 - 8)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - 8). It is obtained from AUC (0 - t) plus AUC (t - 8).", 
                "measure": "Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - 8)]", 
                "safety_issue": "No", 
                "time_frame": "7 days"
            }, 
            {
                "measure": "Maximum Observed Plasma Concentration (Cmax)", 
                "safety_issue": "No", 
                "time_frame": "7 days"
            }, 
            {
                "description": "AUC (0 - 8)= Area under the plasma radioactivity concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - 8). It is obtained from AUC (0 - t) plus AUC (t - 8).", 
                "measure": "Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - 8)] for total radioactivity related to drug product", 
                "safety_issue": "No", 
                "time_frame": "7 days"
            }, 
            {
                "measure": "Maximum Observed Plasma Concentration (Cmax) for total radioactivity related to drug product", 
                "safety_issue": "No", 
                "time_frame": "7 days"
            }, 
            {
                "description": "Total percentage of dosed radioactivity recovered in urine and feces", 
                "measure": "Cumulative recovery of radioactivity in excreta", 
                "safety_issue": "No", 
                "time_frame": "7 days"
            }, 
            {
                "description": "Total percentage of radioactivity in blood related to drug product", 
                "measure": "Radioactivity in blood", 
                "safety_issue": "No", 
                "time_frame": "7 days"
            }, 
            {
                "description": "Measure of renal clearance (CLr), amount excreted unchanged in urine (Ae) and the fraction of dose excreted unchanged in urine (AE%)", 
                "measure": "Urine PF-04449913 PK parameters", 
                "safety_issue": "No", 
                "time_frame": "7 days"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02110342"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast)", 
                "measure": "Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)", 
                "safety_issue": "No", 
                "time_frame": "7 days"
            }, 
            {
                "description": "Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.", 
                "measure": "Plasma Decay Half-Life (t1/2)", 
                "safety_issue": "No", 
                "time_frame": "7 days"
            }, 
            {
                "description": "Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes.  Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population pharmacokinetic (PK) modeling.  Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.", 
                "measure": "Apparent Oral Clearance (CL/F)", 
                "safety_issue": "No", 
                "time_frame": "7 days"
            }, 
            {
                "description": "plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed.", 
                "measure": "Apparent Volume of Distribution (Vz/F)", 
                "safety_issue": "No", 
                "time_frame": "7 days"
            }
        ], 
        "source": "Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}